Morepen Laboratories’ Q1 FY26 PBT slumped 67.79% YoY amid rising finance costs and employee-related expenses.

• Finance cost soared 250.43% YoY, significantly impacting quarterly profit despite marginal rise in overall expenses.
• Material and employee expenses rose 1.14% and 15.18% YoY respectively, adding to cost pressures in Q1 FY26.
• Global pharma player with strong API and wellness portfolio, Morepen operates in 80+ countries across key healthcare segments.